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Background.Osteoporosisisachronicdiseasethatcansigniﬁcantlyimpactnumerousaspectsofhealthandwellness.Theindividual
consequences of osteoporosis can be devastating, often resulting in substantial loss of independence and sometimes death. One
of the few illnesses with greater disease burden than low bone mineral density (BMD) is major depressive disorder (MDD). Both
depression and antidepressant use have been identiﬁed as secondary causes of osteoporosis. The objective of this paper is to review
and summarize the current ﬁndings on the relationship between antidepressant use and BMD. Methods. Relevant sources were
identiﬁed from the Pubmed and MEDLINE databases, citing articles from the ﬁrst relevant publication to September 1st, 2010.
Results. 2001 articles initially met the search criteria, and 35 studies were thoroughly reviewed for evidence of an association
between SSRI use and BMD, and 8 clinical studies were detailed and summarized in this paper. Conclusions. Current ﬁndings
suggest a link between mental illness and osteoporosis that is of clinical relevance. Additional longitudinal studies and further
research on possible mechanisms surrounding the association between SSRI use on bone metabolism need to be conducted.
Treatment algorithms need to recognize this association to ensure that vulnerable populations are screened.
1.Introduction
Osteoporosis is a chronic disease that aﬀects approximately
26% of women aged 65 years or older [1, 2]. A 50-year-
old woman has approximately a 40% chance of sustaining
an osteoporotic fracture [3, 4], and a 14-year-old girl has a
17% chance of sustaining a hip fracture at some point in
herlifetime[5].Theindividual consequencesofosteoporosis
can be devastating, often resulting in substantial loss of
independence and sometimes death [6] .T h eb u r d e no nt h e
health care system is also substantial, and it is estimated that
the annual cost of hip fractures could exceed $2.4 billion by
2041 [7]. It is also an illness that is preventable if identiﬁed
early and managed appropriately.
One of the few illnesses with greater disease burden
than low bone mineral density (BMD) is major depressive
disorder (MDD); it has been projected that MDD will be
the biggest cause of disability world wide by 2020 [8].
Importantly, this is not simply attributed to psychiatric
morbidity, and, in fact, MDD has been linked to a host of
physical illnesses, mitigated in large extent by side eﬀects
of pharmacotherapy [9]. Recent evidence highlights the fact
that impaired bone health may soon be joining this growing
list.
1.1. Evidence of an Association between Antidepressant Use
a n dB o n eH e a l t h .Serotonin (5-hydroxytryptamine; 5-HT)
is a neurotransmitter produced primarily in serotonergic
neurons in the central nervous system (CNS). Its primarily
role is to inﬂuence psychological and behavioural functions
such as mood, anxiety, and sleep, and, as a consequence, it
is a key player in the pathophysiology of MDD and other
psychiatric illnesses [10–14]. Therefore, not surprisingly, a
wide range of psychiatric disorders are treated with drugs
that target this system [14–17].
Selective serotonin reuptake inhibitors (SSRIs) repre-
sent a class of medications that selectively and potently
block the serotonin transporter (5-HTT) in the CNS to2 Journal of Osteoporosis
eﬀectively increase the extracellular levels of serotonin and
relieve symptoms of depression [12]. The primary target of
SSRIs are serotonin transporters (SERT), and the general
principle of the SSRIs’ mechanism of action is to boost
the synaptic activity of serotonin by acute pharmacological
inhibition of presynaptic SERTs, thereby increasing the
synaptic concentration and activity of serotonin [12, 18–
22]. As a result of elevated central serotonin, depressive
symptoms are alleviated. The impact of serotonin 5-HT is
not conﬁned to the CNS, however, and a functional 5-HT
signaling system in bone was identiﬁed in 2001 [23, 24].
Further investigation of this peripheral 5-HT system has also
shownthatSSRIsappeartoaﬀectbothCNSandbone5-HTT
with similar potency [23]. While the speciﬁc biochemical
nature of serotonergic pathways and their direct and/or
indirect eﬀects on bone metabolism are still unclear, existing
datasuggestanassociationbetweendepressionandincreased
risk of fracture and bone loss that may be mediated in part
by antidepressants [16].
1.2. The Role of Serotonin in Bone Health. A functional
role for 5HT in bone was ﬁrst documented in 2001
when Bliziotes and colleagues demonstrated the presence of
neurotransmitters, receptors, and transporters in osteoblasts
and osteoclasts [23, 25, 26]. This group documented that
the serotonergic system in bone plays a critical role in bone
metabolism, a fact that was later conﬁrmed by Westbroek
and colleagues [23, 24]. Their ﬁndings also revealed that
knockout mice without the serotonin transporter demon-
strated signiﬁcant decreases in bone density, impaired bone
architecture, and bone mechanical properties [23]. Bliziotes’
group also suggested that one possible mechanism to explain
5HT’s negative eﬀe c to nb o n ei st h er e d u c t i o ni no s t e o b l a s t
activity, as a result of serotonin transporter inhibition,
leading to lower BMD. This work provided evidence of
the role serotonin in bone metabolism and a mechanism
through which SSRIs may inﬂuence bone health [23].
Work on the link between depression, SSRI use, and BMD
is equivocal; however, no association was noted between
antidepressant use and BMD among men and women 17
years of age and older using data from the Third National
Health and Nutrition Examination Survey (NHANES III)
[27] or among postmenopausal women participating in the
Women’s Health Initiative (WHI) Observational Study [28].
In contrast, a recent meta-analysis identiﬁed depression,
and especially depression in premenopausal women, as a
signiﬁcant risk factor for low BMD [29], while new work on
novel mechanisms of serotonergic modulation of bone mass
[30] highlights the biologic plausibility of an antidepressant
mediated mechanism of decreased BMD.
The risks of low BMD associated with serotinergic
antidepressant use and/or depression needs to be clariﬁed.
The scope of this problem cannot be denied; the use of
antidepressantsisubiquitous,withcombinedAmericansales
that exceeded $10 billion in 2004 [37]; a report published
in 2000 ranked antidepressant drugs third among all drugs
in the US prescription drug sales [38] and listed SSRIs
as the most commonly prescribed class of antidepressants,
accounting for approximately 62% of all antidepressants
prescribed in the United States in 2002 [39]. Therefore, the
goal of this paper is to summarize the literature on the
association between SSRI use and bone health.
2.MaterialsandMethods
2.1. Study Selection. A comprehensive literature search
using the computerized databases Pubmed and MEDLINE
to identify relevant studies, covering the period ending
September 2010, was performed using the medical subject
headings “selective serotonin reuptake inhibitors,” “depres-
sion,” “major depressive disorder,” “antidepressants,” “bone
mineral density,” “osteoporosis,” and “hypothalamic-pituary
adrenal axis.” A manual search of relevant reports was con-
ducted by examining reference lists from original research
papers and review articles. An initial screening was made of
titles and abstractsof thearticles, andsimple relevantcriteria
for human participants, antidepressants, SSRIs, MDD, and
BMD were used to exclude obviously irrelevant references.
Inclusion criteria were (1) English-language journals, (2)
full published studies with original data in peer-reviewed
journals, (3) conﬁrmation of depression with a standardized
diagnostic tool, and (4) treatment with SSRIs. In total, eight
relevant studies were identiﬁed that complied with these
search criteria [16, 17, 31–36].
2.2. Data Extraction. All data were extracted independently
by two investigators (MKC and VHT) using a standard
protocol and data-collection form. Disagreements were
resolved by discussion and, when necessary, by additional
input from a third investigator. The extracted information
included name of ﬁrst author, year of publication, study
design, country where the study was conducted, character-
istics of study subjects (sample size, sampling methods, and
distribution according to gender, mean age, race, weight,
body mass index (BMI), menopausal status (women only),
and antidepressant medication history), measures of BMD
and of depression, confounding factors that were controlled
by matching or multivariate adjustment, and mean BMD
for depressed SSRI-treated, nontreated and nondespressed
persons (if possible).
3. Results
Our initial search on PubMed identiﬁed 2001 potentially
relevant and eligible studies; 35 full text articles were
retrieved and screened for more detailed evaluation. Redun-
dant references were eliminated, and studies that did not
meet the eligibility criteria were excluded; therefore, a total
of eight articles remained [16, 17, 31–36].
The eight articles reviewed in detail were human clinical
studies [16, 17, 31–36]. Six studies examined BMD in SSRI
users compared to nonusers and suggested an association
between SSRI use and lower age- and gender- related BMD
in humans [16, 17, 31, 32, 34, 35]. Richards et al. along
with Ziere et al. also examined the fracture risk in SSRI
users compared to nonusers. These studies suggested anJournal of Osteoporosis 3
association between SSRI use and risk of fractions; however,
onlyonestudyinvestigatedBMDconcomitantlywiththerisk
offalls[17].Oftheeightstudiesidentiﬁed,sevenstudiesused
fan-beam dual energy X-ray absorptiometry (DXA; QDR
4500W,HologicInc.,)tomeasureBMD(g/cm2)[16,17,31–
35] and one used the dual energy X-ray absorptiometry
pencil beam (DPX-L, Lunar Corp., Madison, WI) [36].
Therewerevariousmethodsappliedforassessingdepres-
sive symptoms. Five studies used the Diagnostic and Statisti-
calManualofMentalDisorder(DSM)depressionassessment
criteria [31–35], one study [36] used criteria for depression
according to the Center for Epidemiologic Studies Depres-
sion Scale (CES-D), and others used the Mental Component
Score (MCS), the Mental Health Inventory 5 (MHI-5) scales
of the Medical Outcomes Study 36-Item Short-Form Health
Survey questionnaire [17], or the Geriatric Depression Scale
(GDS) [16].
Of the eight human clinical studies reviewed, ﬁve studies
clearly provide support for an association between treatment
with SSRI and lower BMD [16, 17, 32, 34, 36]. In contrast,
three small studies demonstrated no connection between
SSRI treatment and lower BMD [31, 33, 35]. Sample sizes
in the studies selected ranged from 42 to 7983 and, and
six studies were case-control studies and two contained data
from prospective cohorts (Table 1).
4. Discussion
4.1. Clinical Studies Investigating an Association between
SSRI Use and Bone Health. The possibility of an association
between SSRI use and low BMD has sparked a recent
rise in studies investigating the clinical implications of
antidepressant treatment on bone health. In 2005, Cauley
andcolleaguesconductedapopulation-basedcross-sectional
study of participants enrolled in The Osteoporotic Fractures
Study in Men (aged 65 years) to determine the factors
associated with BMD of the lumbar spine and proximal
femur. The authors concluded that SSRI use was indepen-
dently associated with a lower spine and hip BMD [32]
but it was noted that the weight loss and poor diet in
persons with depression could have confounded the results
observed. A separate study was conducted by Diem et al.
to determine whether SSRI use in a cohort of 2744 women
(65 years) enrolled in the Study of Osteoporotic Fractures
was associated with increased rates of bone loss, speciﬁcally
in the hip. Patients in the study were divided into either
“partial users” where SSRI use was recorded at one of the
two visits only or “recurrent users” where SSRI use was
recordedatbothvisits[16].Thestudycoveredaperiodof4.9
years, and BMD of the total hip and 2 subregions (femoral
neck and trochanter) was assessed with serial measurements
over 2 separate visits. The end result was that SSRI use in
women was independently associated with increased rates
of hip bone loss compared to nonusers [16]. An analysis
of the Canadian Multicentre Osteoporosis Study (CaMos)
cohort revealed an association between SSRI use and lower
BMD that was related to increased clinical fragility fracture
risk [17]. Consistent with the ﬁndings revealed by Richards
et al. [17]a n dD i e me ta l .[ 16], the results from a large
cohort study conducted in Rotterdam demonstrated that
the use of SSRIs was associated with a 2.25-fold increase in
fracture risk [36]. Of note, the authors in this study were able
to distinctly deﬁne a direct correlation between treatment
duration and greater fracture risk, which was detectable as
early as 6 weeks following treatment. Furthermore, a similar
trend was observed in an observational study conducted by
Williams et al. to investigate the eﬀect of SSRIs on BMD in
women with a lifetime history of depressive disorder (SSRI-
treated group and untreated) [34]. The results indicated that
BMD among SSRI users was 5.6% ((0.977 (0.116) versus
0.922 (0.117) g/cm2, P = 0.03)) lower at femoral neck, 6.2%
(0.813 (0.105) versus 0.763 (0.107) g/cm2, P = 0.04)) lower
at the trochanter, and 4.4% ((0.745 (0.007) versus 0.712
(0.068) g/cm2, P = 0.03)) lower at mid-forearm compared
to SSRI nonusers [34]. Based on these ﬁndings, Williams and
colleagues concluded that SSRIs negatively impacts BMD
independent of the eﬀect of depression on bone health. Of
the above-mentioned studies, Williams et al. is the only
study in which depressed patients were diagnosed according
to the DSM-IV [34]. Interestingly, according to Bab and
Yirmiya, the strength of an association is stronger, displaying
signiﬁcantly lower BMD, when patients were diagnosed with
MDD by clinical assessment as opposed to being diagnosed
by self-rated questionnaires [40].
Inconsistency exists in observations of an association
betweenSSRIuseandreducedBMD,withthreesmallstudies
demonstrating a relationship [31, 33, 35]. In a study of
the association between depression and BMD, 24 women
with past or current MDD were matched with 24 healthy
controls, with 15 of the depressed women reporting SSRI
use [31]. Those women with current or past depression
had lower trabecular bone density as compared to healthy
controls,but,aftercontrollingforageandBMI,BMDdidnot
correlate with the duration of antidepressant drug therapy.
The authors ultimately reported no association between
a lifetime use of antidepressant drug treatment and bone
density [31]. Similarly, Eskandari and colleagues conducted
a prospective study in premenopasal women in which they
examined the association between MDD and BMD using
immune, pituitary-adrenal, and sympatheticbiomarkers to
determine whether this population had a higher prevalence
of osteopenia and osteoporosis and lower BMD than healthy
controls [33]. While an association between premenopausal
women with MDD and lower bone mass was conﬁrmed, like
the Michelson study, no association was reported between
S S R I su s ea n dB M D[ 33]. A limitation of this study as
indicated by the authors is that women with MDD in
their cohort had approximately 5kg higher body mass
than in other studies cohorts. This may have resulted in
the lack of an association between SSRI use and BMD,
given that higher body mass positively aﬀects BMD [33].
Further support for these observations is found in the cross-
sectional study of premenopausal women with unipolar
depressionmatchedwithhealthycontrolswhodemonstrated
signiﬁcantlylowerBMD.Afteradjustingfordurationofdrug
exposure, however, it appeared that antidepressants had no
impact on the osteodensitometric results [35]. In contrast to4 Journal of Osteoporosis
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these 3 studies, a study conducted by Kavuncu et al. using a
similarsampleofpatientstakingSSRIsreportedgreaterbone
resorption [41].
5. Limitations
MDD aﬀects as many as 16% of adult in the US [42],
with prevalence increasing as the population ages [43].
Depression has also been linked to a reduced BMD in
some [16, 17, 32, 34, 36], but not all [31, 33, 35] studies.
Therefore, a diﬃcult task when deﬁning the association
between treatment with SSRI and lower BMD is controlling
for confounding factors. Several clinical studies involving a
population of depressed subjects to examine BMD in SSRI
users and nonusers, however, have demonstrated that SSRIs
may independently impact bone health, while physiologic
and hormonal changes associated with depressive symptoms
may magnify the adverse side eﬀects of SSRI [16, 17, 32,
34, 44, 45]. Therefore, it is possible that depression, in
combination with SSRI treatment, may have an additive
negative eﬀect on BMD. Accordingly, an investigation of the
potential contribution of mental illness a subsequent SSRI
treatment as a determinant of bone health is warranted.
6. Conclusion
The vastly growing body of research on SSRIs and its eﬀect
on bone health suggests that this relationship is complex
and interpreting these ﬁndings has proved to be challeng-
ing. Although multiple consistent ﬁndings reveal a trend
suggesting that SSRI use may negatively impact bone and
result in lower BMD, a deﬁnitive causal relationship cannot
be drawn. The distinct fact that depression itself, both as
a consequence of innate biological changes that accompany
the illness and secondary to lifestyle factors such as poor
diet and lack of activity that often are linked to depression,
has been shown to cause bone loss poses depression as a
confounding variable in epidemiologic studies investigating
the exact eﬀects of SSRIs on bone health. While it may be too
soon to infer causality, however, the burgeoning mountain of
evidence consistently demonstrating an association between
SSRI use and bone loss now seems suﬃcient to consider
adding SSRIs to the list of medications that contribute
to osteoporosis. This would imply that clinicians consider
bone density testing for people on SSRIs, or those on
SSRIs with certain additional risk factors, for their risk of
fracture. Further investigations are needed to conﬁrm the
serotoninergic eﬀects on bone to deﬁnitely guide physicians
to provide clear recommendations to patients regarding the
clinical implications associated with SSRI treatment. It is
also necessary to continue future investigations to deﬁnitely
prove a casual connection between SSRI use and bone,
and furthermore, to conﬁrm the recent promising animal
ﬁndings that may potentially prevent and treat bone loss.
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